TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01239030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate Hydrochloride Extended Release Capsules
Description: Biphentin Methylphenidate ER Once-A-Day Capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate Hydrochloride Extended Release Capsules
Description: Biphentin Methylphenidate ER Once-A-Day Capsules
Study: NCT03486080

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dutogliptin Tartrate
Description: Active treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim Injectable Product
Description: Active treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebo control
Study: NCT04532008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group based treatment
Description: 12 sessions of group based therapy that included cognitive restructuring, behavioral activation, and interpersonal therapy
Study: NCT02417142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Exenatide SQ 2mg/week for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo SQ 1x/week for 24 weeks.
Study: NCT01239030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate Hydrochloride Extended Release Capsules
Description: Biphentin Methylphenidate ER Once-A-Day Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Hydrochloride Extended Release Capsules
Description: Biphentin Methylphenidate ER Once-A-Day Capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT03211286

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: 1 g of intravenous tranexamic acid in 100 mL of saline solution
Study: NCT02948322

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CMRI
Description: Myocardial Imaging (CMRI) will be performed in patients (at baseline and 6 month after treatment) and healthy volunteers (baseline)
Study: NCT03211286

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: saline solution 100 mL intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline Solution
Description: saline solution 100 mL intravenous
Study: NCT02948322

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CMRI
Description: Myocardial Imaging (CMRI) will be performed in patients (at baseline and 6 month after treatment) and healthy volunteers (baseline)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: gadolinium injection will be performed during CMRI in patients and healthy volunteers.
Study: NCT00645099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: 10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paliperidone ER
Description: 6-mg or 9-mg tablet once daily flexible dosing for 6 months
Study: NCT02948322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gadolinium
Description: gadolinium injection will be performed during CMRI in patients and healthy volunteers.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OGTT
Description: Growth Hormon (GH) secretion and metabolic status of the acromegalic will be evaluated by an measure of plasma glucose, insulin and GH (OGTT), and insulin-like growth factor-1 (IGF-I) will be measured in patients and healthy volunteers.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OGTT
Description: Growth Hormon (GH) secretion and metabolic status of the acromegalic will be evaluated by an measure of plasma glucose, insulin and GH (OGTT), and insulin-like growth factor-1 (IGF-I) will be measured in patients and healthy volunteers.
Study: NCT02539095

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CartiZol
Description: The product, CartiZol, which contains absorbable collagen, is applied on the cartilage defect to stimulate the neovasculization and cell penetration and to assist the natural wound healing process. It supplements the defective or damaged cartilage. Place the needle on the tip of the syringe and inject the product into the articular cavity.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 1. Supplementation of fluid and electrolytes (sodium or chlorine deficiency)~2. Diluent for injection solution Place the needle on the tip of the syringe and inject the product into the articular cavity.
Study: NCT02044978

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronate-coated dental implant
Study: NCT04170699

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Port-a-cath replacement
Description: Implantation of a subcutaneous venous port-a-cath

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Port-a-cath replacement
Description: Implantation of a subcutaneous venous port-a-cath
Study: NCT00962000

Intervention type: OTHER
Group type: OTHER
Intervention: Dialysis Flow Rate Start 600mL/min
Description: ABAB sequence where A represents three consecutive dialysis treatments with a dialysate flow rate of 600 mL/min and B represents three consecutive treatments with a dialysate flow rate of 800 mL/min.

Intervention type: OTHER
Group type: OTHER
Intervention: Dialysis Flow Rate Start 800mL/min
Description: BABA sequence where B represents three consecutive treatments with a dialysate flow rate of 800 mL/min and A represents three consecutive dialysis treatments with a dialysate flow rate of 600 mL/min.
Study: NCT00880282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cixutumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01539109

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Rehabilitation
Description: Patients will receive training upon tasks of daily living. Patients will perform these exercises in our laboratory under the supervision of qualified personnel.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Patients will receive training upon tasks of daily living. Patients will perform these exercises in our laboratory under the supervision of qualified personnel.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Noninvasive brain stimulation: tDCS
Description: TDCS is a method of noninvasive stimulation of the brain. Using electrodes placed in saline-soaked sponges, low level of direct current (2mA) is delivered over the scalp. This intervention is considered safe and noninvasive because it does not involve implantation or injection or any skin penetration. In the present study, tDCS will be delivered to patients in the experimental group for 2 hr each day for 5 days a week for 2 weeks in conjunction with therapy for the affected hand.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS: placebo noninvasive brain stimulation
Description: Placebo set-up for noninvasive brain stimulation will be similar to that for the active tDCS; sponge electrodes would be placed on the scalp and connected to a batter-operated device. Patients will not receive the effective level of direct current as would delivered in active tDCS intervention. But patients will not be able to decipher whether they are receiving active or placebo tDCS.
Study: NCT02153736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPEEDI Intervention
Description: Behavioral intervention provided through a collaboration between the mother of enrolled subjects and a physical therapist. Intervention starts in the Neonatal Intensive Care Unit and continues after discharge. SPEEDI includes both parent education and developmental activities.
Study: NCT04380922

Intervention type: OTHER
Intervention: Periodontal screening
Description: Periodontal data collection (PPD, REC, CAL)

Intervention type: OTHER
Intervention: Periodontal screening
Description: Periodontal data collection (PPD, REC, CAL)
Study: NCT01634126

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 1 FIT kit
Description: Patient receives 1 FIT

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 2 FIT kit
Description: Patient receives 2 FIT kits
Study: NCT01938612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 will be administered by IV infusion every 14, 21 or 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 will be administered by IV infusion every 14, 21 or 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 will be administered by IV infusion every 14, 21 or 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 will be administered by IV infusion every 14, 21 or 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tremelimumab
Description: tremelimumab is administered by IV infusion every 4 weeks
Study: NCT00500942

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires about the pain level experienced during and after standard procedures are performed in the IR.
Study: NCT00378989

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Consultation at the occupational health services
Description: Consultation at the occupational health services
Study: NCT04568135

Intervention type: OTHER
Intervention: survey
Description: survey
Study: NCT04726020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive monitoring
Description: periodic and planned monitoring nurse intervention with phone call

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard monitoring
Description: standard monitoring of adverse event reaction
Study: NCT01018394

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine lozenges
Description: 4 mg nicotine lozenges for a maximum duration of 12 weeks used ad lib - up to 8 nicotine lozenges per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tobacco-free snuff
Description: Tobacco-free snuff used ad lib for a maximum of 12 weeks
Study: NCT03176836

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole body STIR MRI
Description: Standard technique that detects abnormalities related to excess of water in tissues (edema).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: DW-MRI
Description: MRI technique that analyzes areas of dead cells within tissues, present in some types of tumor.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET-MRI
Description: MRI technique that detect's the cells' use of glucose, more intensely in harmful cells.
Study: NCT01441102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan hydrobromide
Description: Participants instructed to take 60 mg dextromethorphan capsules orally two times a day for 24 months.
Study: NCT04084314

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Erenumab was supplied as a pre-filled pen (auto-injector) for subcutaneous injection.
Study: NCT01218126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losmapimod
Description: comparison of different dosages of drug 2.5 mg, 7.5 mg or 15 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losmapimod
Description: comparison of different dosages of drug 2.5 mg, 7.5 mg or 15 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losmapimod
Description: comparison of different dosages of drug 2.5 mg, 7.5 mg or 15 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo comparison with active
Study: NCT01752673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visualized pulmonary embolism computer task model
Description: This group of participants was presented and trained to use a visual representation of diagnostic pathway for pulmonary embolism. The design of this visual representation is based on Bayes theorem and cognition enhancing visual design principles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Didactic review lecture
Description: This group of participants was presented with a didactic lecture covering the diagnostic approach of pulmonary embolism.
Study: NCT03157518

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Seeking Health Probiota Bifido
Description: • This is a proof of concept study to demonstrate that oral probiotic use can modulate the airway microbiome. After informed consent has been obtained, this study will consist of 2 visits over a four week time period. Each visit will include a blood draw (30ml) and a research bronchoscopy/ bronchoalveolar lavage (BAL) (200ml) visit . A urine pregnancy test will be done on all females of childbearing potential prior to the first BAL as well as a CBC, BMP, and blood clotting tests in all participants. Following the first BAL, subjects will be asked to take an over the counter probiotic supplement (Seeking Health Probiota Bifido) nightly which will be provided to the participant by the study coordinator until the 2nd BAL is performed 4 weeks after the first BAL.
Study: NCT03732183

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Podcast SMART-3RP
Description: 28 daily podcasts, each 15 minutes.
Study: NCT01761097

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endocuff attachment
Description: Endocuff
Study: NCT04653766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ir-CPI - Dose 1
Description: 6 participants received a single intravenous dose of 1.5 mg/kg of Ir-CPI during 6 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ir-CPI - Dose 2
Description: 6 participants received a single intravenous dose of 3.0 mg/kg of Ir-CPI during 6 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ir-CPI - Dose 3
Description: 6 participants received a single intravenous dose of 6.0 mg/kg of Ir-CPI during 6 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ir-CPI - Dose 4
Description: 6 participants received a single intravenous dose of 9.0 mg/kg of Ir-CPI during 6 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For each dose group, 2 additional participants received a single intravenous dose of placebo during 6 hours (8 in total).
Study: NCT02381886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDH305
Study: NCT03088826

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: 15mg PO morphine sulfate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: 10mg Oxycodone
Study: NCT05566093

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-guided ethanol ablation
Description: After puncturing with the needle, 95% ethanol under the guidance of EUS was injected into the tumor. The injection volume of ethanol was estimated according to the following principles: (1) The injection volume was not larger than the tumor spherical volume. (2) Injection volume was reduced when the tumor was adjacent to the pancreatic duct or vessel. (3) Injection volume for the lesions with repeated EUS-FNI was reduced.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-guided lauromacrogol ablation
Description: After puncturing with the needle, lauromacrogol under the guidance of EUS was injected into the tumor. The injection volume of lauromacrogol was estimated according to the following principles: (1) The injection volume was not larger than the tumor spherical volume. (2) Injection volume was reduced when the tumor was adjacent to the pancreatic duct or vessel. (3) Injection volume for the lesions with repeated EUS-FNI was reduced.
Study: NCT03088826

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 650 mg Acetaminophen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 650 mg Acetaminophen
Study: NCT01163370

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine supplementation
Description: 20g/d for 7 days followed by 5g/d for 23 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine supplementation
Description: 20g/d for 7 days followed by 5g/d for 23 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: exercise training
Description: resistance training twice a week for 24 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training
Description: resistance training twice a week for 24 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo (dextrose)
Description: 20g/d for 7 days followed by 5g/d for 23 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo (dextrose)
Description: 20g/d for 7 days followed by 5g/d for 23 weeks
Study: NCT02036489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-asparaginase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARA-C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hidrocortisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP-16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexametasone
Study: NCT00808275

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary calcium
Description: Dairy and non-dairy calcium provided as a part of diet in the amounts of 500 mg/day and 1500 mg/day. Diet contained 70% of daily caloric requirements.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary calcium
Description: Dairy and non-dairy calcium provided as a part of diet in the amounts of 500 mg/day and 1500 mg/day. Diet contained 70% of daily caloric requirements.
Study: NCT06580639

Intervention type: OTHER
Intervention: No intervention.
Description: Blood sampling for analysis of mycobacterial growth inhibition assay (MGIA) analysis.

Intervention type: OTHER
Intervention: No intervention.
Description: Blood sampling for analysis of mycobacterial growth inhibition assay (MGIA) analysis.

Intervention type: OTHER
Intervention: No intervention.
Description: Blood sampling for analysis of mycobacterial growth inhibition assay (MGIA) analysis.

Intervention type: OTHER
Intervention: No intervention.
Description: Blood sampling for analysis of mycobacterial growth inhibition assay (MGIA) analysis.
Study: NCT03973008

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant Chemoradiotherapy
Description: DT 45Gy/25F/5W, using IMRT technology, synchronous tegio single drug chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant Chemotherapy
Description: Oxalis 130mg/m2 intravenous drip on day 1, tegio 80-120 mg daily, twice, half an hour after breakfast and dinner, for 14 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant Chemotherapy
Description: Oxalis 130mg/m2 intravenous drip on day 1, tegio 80-120 mg daily, twice, half an hour after breakfast and dinner, for 14 consecutive days
Study: NCT03207659

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Basketing in RIRS
Description: Treament of renal stones by fragmentation of stone under direct vision through a flexible ureteroscope and then actively extracting them using a basket

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dusting in RIRS
Description: Treament of renal stones by dusting the stone under direct vision through a scope and then leaving them to pass spontaneously
Study: NCT02780700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study: NCT02944643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness and Support Groups
Study: NCT02768623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist led Asthma Management

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist Intervention (when requested by patient)
Study: NCT03230708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erythrocytes derived MPs containing MTX
Description: General conventional treatment and peritoneal drainage, additional peritoneal perfusion with erythrocytes derived MPs containing MTX

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: convention drugs
Description: according to usage method of drugs
Study: NCT01769300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical decision support for medication titration
Description: Electronic health record-based clinical decision support for ADHD medication titration.
Study: NCT04445636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Caudal block with Dexametomedine as an adjuvant to bupivacaine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Addition of morphine as adjuvant to bupivacaine during caudal block.
Study: NCT03058588

Intervention type: GENETIC
Intervention: Analysis with molecular biology
Description: Molecular screening by next generation sequencing (NGS) platform, for known and unknown mutations potentially associated with the disease
Study: NCT03965897

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Committment Therapy (ACT)
Description: Overall, the goal of the ACT intervention is to cultivate psychological flexibility: to help Veterans respond to life events in ways which do not exacerbate difficulties or restrict engagement in meaningful activities. It increases patients' awareness of behaviors that exacerbate the pain (such as struggling with it) and recognition of avoidance strategies that interfere with life engagement.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control (AC)
Description: Information on any other coping practices will be omitted. The group facilitators will present one topic at a time, using the Pain Manual, and the participants will discuss and reflect about issues and experiences related to each topic. If necessary, the group facilitators will raise specific discussion questions to facilitate group dialogue and participant involvement.